HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Piotr Bartnicki Selected Research

4-hydroxyhippuric acid

12/2017Hemodialysis Decreases the Concentration of Accumulated Plant Phenols in the Plasma of Patients on Maintenance Dialysis: Influence of Residual Renal Function.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Piotr Bartnicki Research Topics

Disease

4Chronic Renal Insufficiency
02/2018 - 11/2013
4Chronic Kidney Failure (Chronic Renal Failure)
02/2018 - 01/2017
2Cardiovascular Diseases (Cardiovascular Disease)
10/2016 - 01/2016
2Anemia
10/2015 - 11/2013
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2021
1Glomerulonephritis
04/2021
1Hypertension (High Blood Pressure)
04/2021
1Melanoma (Melanoma, Malignant)
04/2021
1Neoplasms (Cancer)
04/2021
1Interstitial Nephritis (Tubulointerstitial Nephritis)
04/2021
1Proteinuria
04/2021
1Colorectal Neoplasms (Colorectal Cancer)
04/2021
1Acute Kidney Injury (Acute Renal Failure)
04/2021
1Inflammation (Inflammations)
02/2020
1Fibrosis (Cirrhosis)
02/2020
1Atherosclerosis
02/2020
1Oliguria
12/2017
1Autosomal Dominant Polycystic Kidney (ADPKD)
10/2016
1Renal Insufficiency (Renal Failure)
02/2006

Drug/Important Bio-Agent (IBA)

3continuous erythropoietin receptor activatorFDA Link
01/2016 - 11/2013
2Biomarkers (Surrogate Marker)IBA
02/2020 - 01/2016
1Irinotecan (Camptosar)FDA LinkGeneric
04/2021
1Oxaliplatin (Eloxatin)FDA LinkGeneric
04/2021
1Gefitinib (Iressa)FDA Link
04/2021
1Vinorelbine (Navelbine)FDA LinkGeneric
04/2021
1NivolumabIBA
04/2021
1atezolizumabIBA
04/2021
1RamucirumabIBA
04/2021
1Antineoplastic Agents (Antineoplastics)IBA
04/2021
1GemcitabineFDA Link
04/2021
1cyclopropapyrroloindoleIBA
04/2021
1pembrolizumabIBA
04/2021
1Bevacizumab (Avastin)FDA Link
04/2021
1Capecitabine (Xeloda)FDA Link
04/2021
1Erlotinib Hydrochloride (CP 358,774)FDA Link
04/2021
1IpilimumabIBA
04/2021
1Cisplatin (Platino)FDA LinkGeneric
04/2021
1ElectrolytesIBA
04/2021
1ElementsIBA
04/2021
1Etoposide (VP 16)FDA LinkGeneric
04/2021
1Carboplatin (JM8)FDA LinkGeneric
04/2021
1Paclitaxel (Taxol)FDA LinkGeneric
04/2021
1Topotecan (Hycamtin)FDA LinkGeneric
04/2021
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2021
1Urokinase Plasminogen Activator ReceptorsIBA
02/2018
1C-Reactive ProteinIBA
01/2018
1Lipopolysaccharide ReceptorsIBA
01/2018
1Mannose-Binding Lectin (Mannan-Binding Lectin)IBA
01/2018
1AcidsIBA
12/2017
14-hydroxyhippuric acidIBA
12/2017
1PhenolsIBA
12/2017
1PolyphenolsIBA
12/2017
1Vanillic AcidIBA
12/2017
1Uric Acid (Urate)IBA
01/2017
1Lipoproteins (Lipoprotein)IBA
01/2017
1TolvaptanFDA Link
10/2016
1LipidsIBA
10/2016
1Angiotensin Receptor AntagonistsIBA
10/2016
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
10/2016
1Drug CombinationsIBA
10/2016
1TEMPOIBA
10/2016
1Edetic Acid (EDTA)FDA Link
10/2016
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
10/2016
1HematinicsIBA
10/2015
1AntioxidantsIBA
11/2013
1Inositol (Myoinositol)IBA
02/2006

Therapy/Procedure

2Renal Dialysis (Hemodialysis)
02/2018 - 12/2017
1Aftercare (After-Treatment)
04/2021
1Drug Therapy (Chemotherapy)
04/2021
1Immunotherapy
04/2021